Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-KHK in Overweight/Obese Volunteers and T2DM Patients
NCT05761301Phase 2Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of ALN-KHK in type 2 diabetes mellitus (T2DM), sponsored by Alnylam Pharmaceuticals. Started Mar 2023; status: terminated.
02
Drugs
ALN-KHK
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05761301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761301.